JP6946575B2 - 眼の状態の治療のためのピロカルピン塩酸塩の使用 - Google Patents

眼の状態の治療のためのピロカルピン塩酸塩の使用 Download PDF

Info

Publication number
JP6946575B2
JP6946575B2 JP2020559558A JP2020559558A JP6946575B2 JP 6946575 B2 JP6946575 B2 JP 6946575B2 JP 2020559558 A JP2020559558 A JP 2020559558A JP 2020559558 A JP2020559558 A JP 2020559558A JP 6946575 B2 JP6946575 B2 JP 6946575B2
Authority
JP
Japan
Prior art keywords
volume
weight
pharmaceutical composition
eye
pilocarpine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522256A (ja
Inventor
マイケル アール ロビンソン
マイケル アール ロビンソン
モハメド ディバス
モハメド ディバス
ジャヤ ギヤナニ
ジャヤ ギヤナニ
アヌラーダー ゴア
アヌラーダー ゴア
ソンウク リー
ソンウク リー
ハイシア リウ
ハイシア リウ
アイリーン モーガン
アイリーン モーガン
ジハオ チョウ
ジハオ チョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66821312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6946575(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2021522256A publication Critical patent/JP2021522256A/ja
Priority to JP2021150116A priority Critical patent/JP7470667B2/ja
Application granted granted Critical
Publication of JP6946575B2 publication Critical patent/JP6946575B2/ja
Priority to JP2024062082A priority patent/JP2024096131A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020559558A 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用 Active JP6946575B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021150116A JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862662144P 2018-04-24 2018-04-24
US62/662,144 2018-04-24
US201862780117P 2018-12-14 2018-12-14
US62/780,117 2018-12-14
US201962790957P 2019-01-10 2019-01-10
US62/790,957 2019-01-10
PCT/US2019/028917 WO2019209955A2 (en) 2018-04-24 2019-04-24 Presbyopia treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021150116A Division JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用

Publications (2)

Publication Number Publication Date
JP2021522256A JP2021522256A (ja) 2021-08-30
JP6946575B2 true JP6946575B2 (ja) 2021-10-06

Family

ID=66821312

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020559558A Active JP6946575B2 (ja) 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2021150116A Active JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A Pending JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021150116A Active JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A Pending JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Country Status (25)

Country Link
US (4) US10610518B2 (enExample)
EP (2) EP4066830A1 (enExample)
JP (3) JP6946575B2 (enExample)
KR (2) KR20210005134A (enExample)
CN (1) CN112272558A (enExample)
AU (3) AU2019261598B9 (enExample)
BR (1) BR112020021845A2 (enExample)
CA (2) CA3162141A1 (enExample)
CL (1) CL2020002734A1 (enExample)
CO (1) CO2020014563A2 (enExample)
CY (1) CY1125325T1 (enExample)
DK (1) DK3681500T3 (enExample)
ES (1) ES2920803T5 (enExample)
HR (1) HRP20220762T1 (enExample)
HU (1) HUE058931T2 (enExample)
IL (1) IL278178A (enExample)
LT (1) LT3681500T (enExample)
MX (1) MX2020011301A (enExample)
PH (1) PH12020551766A1 (enExample)
PL (1) PL3681500T3 (enExample)
PT (1) PT3681500T (enExample)
RS (1) RS63360B1 (enExample)
SG (1) SG11202010472XA (enExample)
SI (1) SI3681500T1 (enExample)
WO (1) WO2019209955A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102654048B1 (ko) 2017-07-20 2024-04-03 세인다 파마슈티컬 광저우 코포레이션 근시 치료용 조성물 및 방법
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
CN113164451A (zh) 2018-10-15 2021-07-23 奥库菲尔制药股份有限公司 治疗青光眼的方法和组合物及相关病症
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
AU2021338618B2 (en) * 2020-09-11 2024-02-01 Intratus-Nevada, Inc. Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity
JP2024505517A (ja) * 2021-01-28 2024-02-06 グラウコス コーポレイション 製剤
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
EP4433053A4 (en) 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
CN116350790B (zh) 2021-12-28 2025-02-07 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途
US20230270671A1 (en) * 2022-01-14 2023-08-31 Somerset Therapeutics, Llc Pharmaceutically stable pilocarpine formulations with substantially reduced buffer content and related methods
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
CN119584954A (zh) 2022-04-21 2025-03-07 格劳科斯公司 眼用局部乳膏组合物
CN119546278A (zh) 2022-05-18 2025-02-28 格劳科斯公司 两性离子在眼用局部乳膏组合物和制剂中的新应用
CN117243888A (zh) * 2023-09-22 2023-12-19 南京海纳制药有限公司 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5055467A (en) 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5776916A (en) 1990-07-10 1998-07-07 Gramer; Eugen Medicament for reducing the intraocular pressure
JP2536806B2 (ja) 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1994001096A1 (en) 1992-07-02 1994-01-20 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
SE512871C2 (sv) 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
AU5599594A (en) * 1992-11-16 1994-06-08 Ciba-Geigy Ag Polyvinyl alcohol/borate ophthalmic drug delivery system
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5574518A (en) 1995-01-10 1996-11-12 Les Laboratoires Opti-Centre Inc. System incorporation two different sphero-non-spherical contact lenses for correcting presbytia
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
CH693625A5 (it) 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
IT1306135B1 (it) * 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
EP1214065A4 (en) 1999-09-16 2009-01-07 Ocularis Pharma Inc METHOD USING THE ALPHA AGONIST TO OPTIMIZE THE SIZE OF THE PUPIL
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU2001291159A1 (en) 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
ITMI20010708A1 (it) 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
US20030139737A1 (en) 2002-01-24 2003-07-24 J.T. Lin Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift
ES2397574T3 (es) 2002-07-30 2013-03-08 Omeros Corporation Procedimiento y soluciones de irrigación oftalmológica
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
US20070211212A1 (en) 2002-09-26 2007-09-13 Percy Bennwik Eye state sensor
US20040078009A1 (en) 2002-10-17 2004-04-22 Lin J. T. Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means
US20050205101A1 (en) * 2002-10-17 2005-09-22 Lin J T Combined pharmocological and surgical method and system for the treatment of eye disorders
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
NZ540885A (en) 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
JP4308255B2 (ja) 2004-05-21 2009-08-05 千寿製薬株式会社 ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤
US20050279369A1 (en) 2004-06-21 2005-12-22 Lin J T Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation
JP2008517671A (ja) 2004-10-22 2008-05-29 アキュフォーカス・インコーポレーテッド 光学装置を目の軸に位置合わせするためのシステム及び方法
BRPI0615432A2 (pt) 2005-09-02 2011-05-17 Theravida Inc composição farmacêutica, e, uso de compostos
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
EP1938839B1 (en) 2006-12-18 2009-08-19 Jorge Luis Benozzi Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
BRPI0819081A8 (pt) 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
AU2015202175A1 (en) 2007-12-15 2015-05-14 Anant Sharma Optical correction
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
TW201109325A (en) 2009-07-30 2011-03-16 Wakamoto Pharma Co Ltd Aqueous composition for eye drops
AR081049A1 (es) 2010-08-17 2012-06-06 Gonzalez Santos Alejandro Raul Medicamento oftalmico para el tratamiento de la hipermetropia
US9119772B2 (en) * 2011-01-26 2015-09-01 Allergan, Inc. Androgen composition for treating an opthalmic condition
BR112014006607A2 (pt) 2011-09-20 2017-04-25 Allergan Inc composições e métodos para tratamento de presbiopia, hiperopia leve e astigmatismo irregular
KR20140103099A (ko) 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
RU2014129268A (ru) 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
ES2538551B1 (es) 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
ES2834334T3 (es) 2014-01-10 2021-06-17 Santen Pharmaceutical Co Ltd Preparación farmacéutica que incluye compuesto de ácido piridilaminoacético
CN106456584A (zh) 2014-02-11 2017-02-22 阿拉西斯医药公司 用于矫正老视的药理学眼科用组合物和其施用
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20190000808A1 (en) 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
CN116726006A (zh) 2016-08-19 2023-09-12 阿拉西斯医药公司 眼科药物组合物及其相关用途
EP4241759A1 (en) 2016-10-12 2023-09-13 PS Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Also Published As

Publication number Publication date
LT3681500T (lt) 2022-06-27
AU2020203311A1 (en) 2020-06-11
ES2920803T5 (en) 2025-11-11
EP3681500B2 (en) 2025-07-30
CL2020002734A1 (es) 2021-03-12
EP3681500A2 (en) 2020-07-22
US20190321337A1 (en) 2019-10-24
WO2019209955A2 (en) 2019-10-31
HUE058931T2 (hu) 2022-09-28
KR20230079489A (ko) 2023-06-07
AU2022201106A1 (en) 2022-03-10
US20220241245A1 (en) 2022-08-04
IL278178A (en) 2020-11-30
AU2019261598B9 (en) 2020-05-28
CO2020014563A2 (es) 2021-02-26
EP4066830A1 (en) 2022-10-05
US11285134B2 (en) 2022-03-29
CN112272558A (zh) 2021-01-26
AU2019261598A1 (en) 2020-03-19
HRP20220762T1 (hr) 2022-09-16
RS63360B1 (sr) 2022-07-29
CA3074618A1 (en) 2019-10-31
MX2020011301A (es) 2021-01-29
US10610518B2 (en) 2020-04-07
CA3074618C (en) 2022-08-02
JP2022008403A (ja) 2022-01-13
ES2920803T3 (es) 2022-08-09
JP7470667B2 (ja) 2024-04-18
JP2021522256A (ja) 2021-08-30
CA3162141A1 (en) 2019-10-31
DK3681500T3 (da) 2022-06-27
PT3681500T (pt) 2022-06-27
WO2019209955A3 (en) 2020-01-23
JP2024096131A (ja) 2024-07-12
PH12020551766A1 (en) 2021-07-12
EP3681500B1 (en) 2022-03-23
BR112020021845A2 (pt) 2021-02-23
US20210008034A1 (en) 2021-01-14
KR20210005134A (ko) 2021-01-13
CY1125325T1 (el) 2025-03-28
US20240382462A1 (en) 2024-11-21
PL3681500T3 (pl) 2022-08-01
SG11202010472XA (en) 2020-11-27
SI3681500T1 (sl) 2022-09-30
AU2019261598B2 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP6946575B2 (ja) 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP7297308B2 (ja) 眼科用医薬組成物及びそれに関する使用
JP2022505950A (ja) 老眼、散瞳、および他の眼障害の治療のための方法および組成物
JP2022508715A (ja) 緑内障および関連状態の処置のための方法および組成物
US20220175734A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
Diestelhorst et al. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study
Pepose et al. Reversal of pharmacologically induced mydriasis with phentolamine ophthalmic solution
US20230210821A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
Sowka Phacomorphic glaucoma: case and review
HK40081663A (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
HK40034331A (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
HK40034331B (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
Kim et al. Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration
RU2824137C2 (ru) Способы и композиции для лечения пресбиопии, мидриаза и других глазных расстройств
Wong What's new in contemporary ophthalmic drug delivery systems: Understanding the latest innovative technologies.
Wong What’s new in contemporary ophthalmic drug delivery systems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210915

R150 Certificate of patent or registration of utility model

Ref document number: 6946575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250